Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation.

Javier E OesterheldDamon R ReedBhuvana A Setty Michael S IsakoffPatrick ThompsonHong YinMasanori HayashiDavid M LoebTiffany SmithRikesh MakanjiBrooke L FridleyLars M Wagner

Published in: Pediatric blood & cancer (2020)

In patients with heavily pretreated Ewing sarcoma, the confirmed response rate of 9% was similar to multi-institutional studies of gemcitabine and docetaxel.

Keyphrases

locally advanced
papillary thyroid
rectal cancer
squamous cell
squamous cell carcinoma
quality improvement
childhood cancer
advanced non small cell lung cancer
open label
randomized controlled trial
lymph node metastasis
young adults